AU2011235301B2 - Uses of DGAT1 inhibitors - Google Patents

Uses of DGAT1 inhibitors Download PDF

Info

Publication number
AU2011235301B2
AU2011235301B2 AU2011235301A AU2011235301A AU2011235301B2 AU 2011235301 B2 AU2011235301 B2 AU 2011235301B2 AU 2011235301 A AU2011235301 A AU 2011235301A AU 2011235301 A AU2011235301 A AU 2011235301A AU 2011235301 B2 AU2011235301 B2 AU 2011235301B2
Authority
AU
Australia
Prior art keywords
group
phenyl
substituted
oxadiazol
dgat1 inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011235301A
Other languages
English (en)
Other versions
AU2011235301A1 (en
Inventor
Charles Meyers
Michael H. Serrano-Wu
Tom Thuren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44170024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011235301(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2011235301A1 publication Critical patent/AU2011235301A1/en
Application granted granted Critical
Publication of AU2011235301B2 publication Critical patent/AU2011235301B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2011235301A 2010-03-30 2011-03-29 Uses of DGAT1 inhibitors Ceased AU2011235301B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31881410P 2010-03-30 2010-03-30
US61/318,814 2010-03-30
PCT/US2011/030234 WO2011123401A1 (en) 2010-03-30 2011-03-29 Uses of dgat1 inhibitors

Publications (2)

Publication Number Publication Date
AU2011235301A1 AU2011235301A1 (en) 2012-10-11
AU2011235301B2 true AU2011235301B2 (en) 2013-07-18

Family

ID=44170024

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011235301A Ceased AU2011235301B2 (en) 2010-03-30 2011-03-29 Uses of DGAT1 inhibitors

Country Status (20)

Country Link
US (1) US9061012B2 (enExample)
EP (1) EP2552441B1 (enExample)
JP (2) JP2013523746A (enExample)
KR (1) KR20130073884A (enExample)
CN (1) CN102834099B (enExample)
AU (1) AU2011235301B2 (enExample)
BR (1) BR112012024618A2 (enExample)
CA (1) CA2792269A1 (enExample)
CL (1) CL2012002716A1 (enExample)
ES (1) ES2586127T3 (enExample)
MA (1) MA34097B1 (enExample)
MX (1) MX2012011333A (enExample)
NZ (1) NZ602125A (enExample)
PH (1) PH12012501859A1 (enExample)
RU (1) RU2012145950A (enExample)
SG (1) SG183529A1 (enExample)
TN (1) TN2012000458A1 (enExample)
TW (1) TW201136916A (enExample)
WO (1) WO2011123401A1 (enExample)
ZA (1) ZA201206456B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
JP2015520136A (ja) * 2012-04-25 2015-07-16 コリア リサーチ インスティチュート オブ ケミカル テクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｃｈｅｍｉｃａｌｔｅｃｈｎｏｌｏｇｙ 新規なベータアラニン誘導体、薬学的に許容される塩、及びそれを有効成分として含有する医薬組成物
WO2013169648A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
AU2014216137B2 (en) * 2013-02-14 2018-05-10 Ionis Pharmaceuticals, Inc. Modulation of Apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
WO2015143178A1 (en) 2014-03-20 2015-09-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
HK1231380A1 (zh) * 2014-06-26 2017-12-22 Cymabay Therapeutics, Inc. 严重高甘油三酯血症的治疗
US20180125816A1 (en) 2015-05-11 2018-05-10 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
MY205335A (en) * 2018-03-16 2024-10-16 Anji Pharmaceuticals Inc Compositions and methods for treating severe constipation
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TWI809427B (zh) 2018-07-13 2023-07-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP3886871A4 (en) * 2018-11-30 2022-08-31 HDL Therapeutics, Inc. METHODS OF TREATMENT OF LIPID-RELATED DISEASES, INCLUDING XANTHOMA, CAROTID TENOSIS AND CEREBRAL ATHEROSCLEROSIS
JP2021001143A (ja) * 2019-06-21 2021-01-07 小林製薬株式会社 乳び血漿改善剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007126957A2 (en) * 2006-03-31 2007-11-08 Novartis Ag New compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045439A1 (en) 1996-05-30 1997-12-04 The Trustees Of Columbia University In The City Of New York Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
WO1999067268A1 (en) 1998-06-24 1999-12-29 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
WO2004047755A2 (en) 2002-11-22 2004-06-10 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
DE10331202A1 (de) * 2003-07-10 2005-03-31 S.K. Enterprise Gmbh Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms
EP1653969A4 (en) 2003-08-07 2006-12-20 Japan Tobacco Inc PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
KR20060114376A (ko) 2004-01-30 2006-11-06 니뽄 다바코 산교 가부시키가이샤 식욕 감퇴 화합물
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
EP1764360A4 (en) 2004-07-02 2010-08-11 Sankyo Co UREA DERIVATIVE
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
CN101087769A (zh) 2004-10-15 2007-12-12 拜尔药品公司 用于治疗肥胖的联苯－4－基－羰基氨基酸衍生物的制备及用途
JP2006166742A (ja) * 2004-12-14 2006-06-29 Japan Health Science Foundation 高トリグリセリド血症の成因となる２種類のリポタンパクリパーゼ（ｌｐｌ）遺伝子変異及びそれを利用した高トリグリセリド血症を診断するためのｌｐｌ変異検出キット
CA2588162A1 (en) 2004-12-14 2006-06-22 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
BRPI0913986A2 (pt) * 2008-03-26 2015-10-20 Daiichi Sankyo Co Ltd composto, composição farmacêutica, e, uso de um composto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007126957A2 (en) * 2006-03-31 2007-11-08 Novartis Ag New compounds

Also Published As

Publication number Publication date
KR20130073884A (ko) 2013-07-03
ZA201206456B (en) 2013-05-29
CN102834099B (zh) 2015-05-27
JP6251321B2 (ja) 2017-12-20
TN2012000458A1 (en) 2014-01-30
CL2012002716A1 (es) 2013-01-25
NZ602125A (en) 2014-01-31
US20130023495A1 (en) 2013-01-24
MA34097B1 (fr) 2013-03-05
CA2792269A1 (en) 2011-10-06
SG183529A1 (en) 2012-10-30
EP2552441A1 (en) 2013-02-06
ES2586127T3 (es) 2016-10-11
RU2012145950A (ru) 2014-05-10
JP2016216466A (ja) 2016-12-22
PH12012501859A1 (en) 2013-01-07
MX2012011333A (es) 2012-11-16
EP2552441B1 (en) 2016-05-04
CN102834099A (zh) 2012-12-19
US9061012B2 (en) 2015-06-23
BR112012024618A2 (pt) 2019-09-24
WO2011123401A1 (en) 2011-10-06
TW201136916A (en) 2011-11-01
JP2013523746A (ja) 2013-06-17
AU2011235301A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
AU2011235301B2 (en) Uses of DGAT1 inhibitors
EP1741445B1 (en) Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
US7919484B2 (en) Combination therapy
KR101607081B1 (ko) 디피피-4 저해약과 다른 당뇨병 치료약과의 병용 또는 조합으로 이루어지는 의약
US7834056B2 (en) Pharmaceutical composition for gout
KR20090098877A (ko) 심근 허혈의 예방 또는 치료 방법
EP2968235B1 (en) Combination of canagliflozin and probenecid for the treatment of hyperuricemia
CN120393023A (zh) 组合疗法方法、组合物和试剂盒
US20040102524A1 (en) Method of treatment
US20100056460A1 (en) Combination of organic compounds
JP6429401B2 (ja) 変異を有するｉ型コラーゲンの小胞体内過剰蓄積正常化剤
JP5559696B2 (ja) 糖尿病性腎症の治療剤
Camphor Calciferol See Vitamin D.
Camphor et al. Calamine Zinc carbonate used in dusting powders, creams, lotions, etc. Calciferol See Vitamin D. Calcitonin Hormone from thyroid glands, involved in control of calcium metabolism. Used in treatment of Paget's disease. Calcitriol (la, 25-Dihydroxycholecalciferol) More potent active metabo
MXPA06004020A (en) Pharmaceutical composition comprising an analgesic and vitamins
HK1102424B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
MX2013001354A (es) Composicion farmaceutica oral que contiene una combinacion de un relajante del musculo liso visceral y un analgesico/anti-inflamato rio, y su uso en el tratamiento del sindrome de colon irritable de etiologia diversa.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired